Evaluating therapeutic efficacy against cancer stem cells: new challenges posed by a new paradigm.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 18938746.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Current measures of anticancer drug efficacy reflect bulk cell killing and are poorly suited to detect activity against cancer stem cells (CSCs), which sustain tumor growth. The CSC paradigm necessitates a reexamination of methodologies used to evaluate clinical efficacy of anticancer therapies, as well as strategies employed during preclinical drug development.
Medical subject headings
- Antineoplastic Agents
- Neoplasms
- Neoplastic Stem Cells